Sandbox:ab: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:


==Causes==
==Causes==
===Life Threatening Causes=== <ref name="McMullinBareford2005">{{cite journal|last1=McMullin|first1=Mary F.|last2=Bareford|first2=D.|last3=Campbell|first3=P.|last4=Green|first4=A. R.|last5=Harrison|first5=Claire|last6=Hunt|first6=Beverley|last7=Oscier|first7=D.|last8=Polkey|first8=M. I.|last9=Reilly|first9=J. T.|last10=Rosenthal|first10=E.|last11=Ryan|first11=Kate|last12=Pearson|first12=T. C.|last13=Wilkins|first13=Bridget|title=Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis|journal=British Journal of Haematology|volume=130|issue=2|year=2005|pages=174–195|issn=0007-1048|doi=10.1111/j.1365-2141.2005.05535.x}}</ref>
===Life Threatening Causes===
 


Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
* critical dehydration owing to fluid loss such as severe diarrhea or vomiting, which can result in Spurious Polycythemia
* critical dehydration owing to fluid loss such as severe diarrhea or vomiting, which can result in Spurious Polycythemia
* Severe cyanotic heart diseases with right-to-left shunts
* Severe cyanotic heart diseases with right-to-left shunts
* End-stage cancer related to EPO-secreting tumors such as hepatocellular carcinoma, parathyroid carcinoma, pheochromocytoma, or renal cell carcinoma
* End-stage cancer related to EPO-secreting tumors such as hepatocellular carcinoma, parathyroid carcinoma, pheochromocytoma, or renal cell carcinoma<ref name="McMullinBareford2005">{{cite journal|last1=McMullin|first1=Mary F.|last2=Bareford|first2=D.|last3=Campbell|first3=P.|last4=Green|first4=A. R.|last5=Harrison|first5=Claire|last6=Hunt|first6=Beverley|last7=Oscier|first7=D.|last8=Polkey|first8=M. I.|last9=Reilly|first9=J. T.|last10=Rosenthal|first10=E.|last11=Ryan|first11=Kate|last12=Pearson|first12=T. C.|last13=Wilkins|first13=Bridget|title=Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis|journal=British Journal of Haematology|volume=130|issue=2|year=2005|pages=174–195|issn=0007-1048|doi=10.1111/j.1365-2141.2005.05535.x}}</ref>
 


===Common Causes===
===Common Causes===

Revision as of 22:59, 3 August 2020

Resident Survival Guide
Introduction
Team
Guide
Page Template
Examine the Patient Template
Navigation Bar Template
Checklist
Topics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Polycythemia is defined as increasing the hemoglobin (>16.5 g/dl in men or >16 g/dl in women) or hematocrit level (>49%in men or >48% in women).[1] This elevated level might be due to declining the plasma volume (relative or spurious polycythemia) or rising the number of red blood cells (true polycythemia). [2]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

  • critical dehydration owing to fluid loss such as severe diarrhea or vomiting, which can result in Spurious Polycythemia
  • Severe cyanotic heart diseases with right-to-left shunts
  • End-stage cancer related to EPO-secreting tumors such as hepatocellular carcinoma, parathyroid carcinoma, pheochromocytoma, or renal cell carcinoma[3]


Common Causes

Diagnosis

Shown below is an algorithm summarizing the diagnosis of [[disease name]] according the the [...] guidelines.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Treatment

Shown below is an algorithm summarizing the treatment of [[disease name]] according the the [...] guidelines.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Do's

  • The content in this section is in bullet points.

Don'ts

  • The content in this section is in bullet points.

References

  1. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P; et al. (2018). "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion". Blood Cancer J. 8 (2): 15. doi:10.1038/s41408-018-0054-y. PMC 5807384. PMID 29426921.
  2. Pillai AA, Fazal S, Babiker HM. PMID 30252337. Missing or empty |title= (help)
  3. McMullin, Mary F.; Bareford, D.; Campbell, P.; Green, A. R.; Harrison, Claire; Hunt, Beverley; Oscier, D.; Polkey, M. I.; Reilly, J. T.; Rosenthal, E.; Ryan, Kate; Pearson, T. C.; Wilkins, Bridget (2005). "Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis". British Journal of Haematology. 130 (2): 174–195. doi:10.1111/j.1365-2141.2005.05535.x. ISSN 0007-1048.


Template:WikiDoc Sources